/C O R R E C T I O N - AbbVie/
AbbVie announced its largest-ever ESMO program, with new and updated data across seven solid tumor assets presented at the 2026 ESMO Congress in Madrid (Oct 23-27). Temab-A (telisotuzumab adizutecan) posted strong Phase 1 results: 30% ORR and 14.7-month median OS in colorectal cancer (vs 10.2 months standard of care) and 50-63% ORR in NSCLC, supporting ongoing global Phase 3 trials; the asset recently received two FDA Breakthrough Therapy Designations. ABBV-706 showed a 56% ORR in 2L+ small cell lung cancer (82% in 2L-only), and ABBV-1480 delivered a 61.9% ORR with 15.2-month median PFS in first-line PD-L1-positive NSCLC, both advancing in Phase 3.
Key figures
- Drug Name
- Temab-A (telisotuzumab adizutecan); ABBV-706; ABBV-969; ABBV-1480 (RC148); alveltamig; Emrelis; Elahere
- Phase Of Trial
- Phase 1 data with multiple ongoing Phase 3 studies
- Temab A crc orr
- 30%
- Temab A crc median os
- 14.7 months vs 10.2 months standard of care
- Abbv1480 1 L nsclc orr
- 61.9%
- Abbv706 sclc 2 Lonly orr
- 82%
- Abbv706 sclc 2 Lplus orr
- 56%
- Temab A nsclc egfr wt orr
- 50%
- Temab A nsclc egfr mut orr
- 63%
- Abbv1480 1 L nsclc median pfs
- 15.2 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.